Avivomed, is a medical device company developing innovative neuromodulation technology to treat large disease populations.
Sector: Life Sciences
Neumora Therapeutics
Neumora Therapeutics, Inc. (NASDAQ: NMRA) is a clinical-stage biotechnology company pioneering precision medicines for brain diseases through the integration of data science and neuroscience. Neumora is redefining neuroscience research and development with a data-driven precision neuroscience platform to cut through brain disease heterogeneity to match the right patient populations to targeted therapeutics. The Company’s precision data science platform integrates multiple data types to define patient subtypes through the development of Data Biopsy Signatures™ and Precision Phenotypes™.
RareCyte
RareCyte offers Precision Biology™ solutions focused on multiplexed analysis of cells and tissue with applications in both research and clinical diagnostics. The Company has deep experience in developing advanced precision life science systems used in cutting-edge labs worldwide. RareCyte customers perform innovative research, bring new therapeutics to market, and perform a wide range of single cell applications in oncology and disease research.
Prime Medicine
Prime Medicine (NASDAQ: PRME) is a biotechnology company founded to deliver on the promise of Prime Editing, a versatile gene editing technology that can truly “search and replace” to restore normal genetic function and address the fundamental causes of disease. Prime Medicine envisions a world where Prime Editing can cure or halt disease and provide lifelong benefit to patients—shaping the future of gene editing.
Adela
Adela (formerly DNAMx) is focused on the detection of cancer and other high-morbidity, high-mortality conditions through a routine blood test. The company’s genome-wide methylation analysis technology has the unique ability to distinguish the most-highly informative (methylated) regions of the genome from non-informative regions and preferentially target those informative regions for sequencing.
Garth Rapeport
Garth Rapeport joined F-Prime in 2021 as an Entrepreneur-in-Residence on the healthcare team. Garth is visiting Professor at the National Heart & Lung Institute, Imperial College School of Medicine in London. He was previously co-founder and CEO of Pulmocide and Respivert Ltd. which were drug discovery companies focused on the identification of novel disease modifying treatments for severe asthma and new generation inhaled antiviral and antifungal agents.
Garth is a medical graduate who undertook post-graduate training at the Universities of Glasgow and Oxford. After working at Pfizer Research in the UK he moved to GSK where he was SVP of Drug Discovery in the Respiratory area in which he led the discovery and early development new inhaled therapies for asthma and COPD.
Leyden Labs
Leyden Labs platform targets commonalities of viral families to protect humanity from known and future viruses.
OZiva
OZiva is a plant-based Clean Nutrition Brand. The brand’s core differentiator lies in building a nutrition & fitness ecosystem that combines the best of ancient sciences such as Ayurveda, modern micronutrients, and an instantaneous digital community altogether.
LakeShore Biopharma
LakeShore Biopharma (NASDAQ: LSB), formerly YS Biopharma, is a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and commercializing new generations of vaccines and therapeutic biologics for infectious diseases and cancer
Ensoma
Ensoma is expanding the reach of the curative power of genomic medicine by pioneering a next-generation in vivo approach using its Engenious™ vectors. Ensoma’s vectors are designed to deliver a diverse range of gene modification technologies without the need for stem cell collection or prior myeloablative conditioning (e.g. chemotherapy).